

Luigi Della Gravara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4477290/publications.pdf>

Version: 2024-02-01

18
papers

219
citations

1163117

8
h-index

1058476

14
g-index

18
all docs

18
docs citations

18
times ranked

397
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of combination chemo-immunotherapy in advanced non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 561-568.	2.4	58
2	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression \geq 50% and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	2.6	50
3	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231.	2.8	24
4	Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?. <i>Lung Cancer Management</i> , 2020, 9, LMT22.	1.5	15
5	The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives. <i>Current Clinical Pharmacology</i> , 2020, 15, 11-19.	0.6	14
6	New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1005-1023.	4.1	11
7	Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 120-128.	0.8	11
8	Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer. <i>Drug Safety</i> , 2019, 42, 199-209.	3.2	8
9	Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 87-96.	3.3	5
10	The treatment of advanced lung adenocarcinoma with activating EGFR mutations. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2475-2482.	1.8	5
11	What pharmacotherapeutics should one use for early stage non-small cell lung cancer?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1403-1406.	1.8	4
12	Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 183-189.	2.4	4
13	The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 303-309.	3.1	3
14	First-line treatment of advanced non-small cell lung cancer with ALK rearrangement: state of the art and future development. <i>Expert Review of Respiratory Medicine</i> , 2019, , 1-7.	2.5	2
15	Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients. <i>Journal of Molecular Pathology</i> , 2021, 2, 197-206.	1.2	2
16	Immunotherapy as a targeted therapy in non-small cell lung cancer. <i>Translational Cancer Research</i> , 2018, 8, S70-S75.	1.0	2
17	Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial. <i>Translational Cancer Research</i> , 2019, 8, S145-S148.	1.0	1
18	Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directions. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022, 7, 29-38.	0.7	0